Featured Articles From The Current Issue
GALECTIN-DIRECTED THERAPIES - Targeting Galectin-3 Protein in Drug Development
Peter G. Traber, MD, believes we are only at the beginning of understanding the full potential of gal-3 targeted therapy, and the future likely holds additional high affinity, specific, galectin inhibitors that are bioavailable by routes other than the two currently in development.


>>> See All Cover Stories

Contributor Cindy H. Dubin speaks with some of the leading companies in this market to find out about key trends, packaging advancements, safety improvements, and technology developments.
Cory Berkland, PhD, and Nathan Dormer, PhD, review how controlled-release powders offer a flexible and efficient approach to addressing a multitude of patient populations, while also improving compliance.
Frost & Sullivan Analyst Piyush Bansal says although chemotherapy has been successfully used for inhibiting cell growth throughout the past few decades, the side effects of chemotherapy have forced researchers to look for some alternative drugs (and how to effectively deliver them) for all types of cancer.
Robert A. Preti, PhD, discusses his company’s critical distinction from most other manufacturing partners, steady growth, and the primary challenges facing the cell therapy industry.
Ronald Aung-Din, MD, in view of many documented medical benefits of cannabinoids, but with widely persisting regulations, misinformation, and stigma associated with cannabis, searches for a non-cannabis-derived source of cannabinoid therapy, such as found in β-Caryophyllene.
John L. Allinson, FIBMS, believes despite the increased use of biomarkers, it appears that many researchers are still continuing to use the FDA guidance document for validation even though it only critically addresses the validation of assays to support PK evaluation, and also has a limited scope described within the document in terms of studies where it should be used.
Julian Aleksov, Executive Chairman of Oasmia Pharmaceutical, discusses his company’s efforts to enter the US market, its strategy to increase commercial adoption, and why it believes its underlying drug delivery system technology is significant not only within the oncology sector, but the entire pharmaceutical industry.
Kai Langel believes the remote research model and purpose-built technology offer the tools and the right process to help modernize clinical research and bring it closer to the high standard set by today’s consumer technologies.
John A. Bermingham says with all the fake news today’s media expels at an alarming rate, CEOs should have a plan in place should it one day raise its ugly head in their company.
Contributor Cindy H. Dubin speaks with some of the industry’s leading CDMOs to highlight their capabilities in the areas of speed, quality, technology, and handling of complex APIs.
Detlev Haack, PhD, and Martin Koeberle, PhD, believe one exciting alternative starting to gain traction in the industry is assessment via an electronic tongue to detect and analyze all the compounds responsible for taste within a sample.
Matthew Moorcroft, PhD, warns that in the fast-moving pharmaceutical industry, change is the only constant. And to keep up with market developments, small molecule manufacturers must first understand the trends.
Exclusive Online Content
PCT Now a Global CDMO as Part of Hitachi ChemicalPCT Now a Global CDMO as Part of Hitachi Chemical
PCT announced that Hitachi Chemical Co. America, Ltd. (Hitachi Chemical’s consolidated subsidiary) completed its purchase of the 80.1% remaining membership interest in PCT from Caladrius Biosciences.

First-in-Class Innovation a Key Strategy for Pharmaceutical Companies in a Harsh Market EnvironmentFirst-in-Class Innovation a Key Strategy for Pharmaceutical Companies in a Harsh Market Environment
Fewer than two in 10 medicines exceed the average pharmaceutical R&D cost required to bring a drug to market when the risks of failure to reach market approval are factored in, according to business intelligence provider GBI Research.

Thermo Fisher Scientific to Acquire Patheon for $7.2 BillionThermo Fisher Scientific to Acquire Patheon for $7.2 Billion
Thermo Fisher Scientific Inc., the world leader in serving science, and Patheon N.V., a leading global provider of high-quality drug development and delivery solutions to the pharmaceutical and biopharma sectors, today announced that their boards of directors have approved Thermo Fisher's acquisition of Patheon

Adamas Signs $100-Million Royalty-Backed Note AgreementAdamas Signs $100-Million Royalty-Backed Note Agreement
Adamas Pharmaceuticals, Inc. recenbtly announced that it has entered into a $100-million royalty-backed note agreement with HealthCare Royalty Partners (HCR).

Lupin Announces Opening of New Expansion at its NJ Manufacturing SiteLupin Announces Opening of New Expansion at its NJ Manufacturing Site
The leadership of Lupin Limited gathered along with state and local leaders, including Rep. Bonnie Watson Coleman (DNJ – 12th District), to celebrate the grand opening of the company’s 100,000 square foot expansion of its manufacturing facilities in Somerset.

Aptar Pharma Partners With Kali Care to Develop Real-Time Medication Management Technology Aptar Pharma Partners With Kali Care to Develop Real-Time Medication Management Technology
Aptar Pharma and Kali Care have announced that they entered into a partnership in order to address the challenge of monitoring adherence in ophthalmic clinical trials.

Teneobio's Next Generation T Cell Redirection Antibody Platform for Cancer Biotherapeutics Offers Prospects of Reducing Cytokine ReleaseTeneobio's Next Generation T Cell Redirection Antibody Platform for Cancer Biotherapeutics Offers Prospects of Reducing Cytokine Release
Teneobio, Inc, a next-generation antibody therapeutics company, recently announced the discovery of a large panel of human anti-CD3 binders with diverse affinities and tune-able T-cell activation.

Genisphere Begins Collaborative & Sponsored Research Program With the University of Maryland Genisphere Begins Collaborative & Sponsored Research Program With the University of Maryland
Genisphere LLC, provider of the 3DNA® drug delivery platform, has signed a collaborative and sponsored research agreement with the University of Maryland, through Dr. Silvia Muro.

Pharmatek Adds Further cGMP Spray Drying Capacity in Response to Demand for Improved Pharmaceutical SolubilityPharmatek Adds Further cGMP Spray Drying Capacity in Response to Demand for Improved Pharmaceutical Solubility
Catalent Pharma Solutions recently announced that it is increasing spray drying capacity at its Pharmatek, San Diego, CA, facility with the installation of an additional GEA Niro Mobile Minor unit.

Q BioMed Announces Licensing Agreement Q BioMed Announces Licensing Agreement
Q BioMed Inc. and ASDERA LLC recently announced a licensing agreement that provides Q BioMed with the worldwide exclusive rights to ASDERA's ASD-002, which is being developed to treat a rare pediatric nonverbal disorder. Under the terms of the agreement, Q Biomed receives global rights to develop and commercialize the drug in the rare pediatric disease market.
Market News & Trends

 



Copyright © 2017  Drug Development & Delivery All Rights Reserved. Privacy Policy / Terms and Conditions